
The HemOnc Pulse
The ABCs of MM Treatment According to Rafael Fonseca, MD
Oct 5, 2023
Dr. Rafael Fonseca, an expert in multiple myeloma treatment, discusses the future of MM treatment, the debate between CAR-T therapies and bispecifics, the role of measurable residual disease (MRD), the potential for bispecific therapies to democratize access to advanced treatments, and the paradigm shift toward prioritizing deeper responses, including MRD negativity, for long-term cure in myeloma patients.
29:24
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The future of multiple myeloma (MM) treatment may see chimeric antigen receptor (CAR)-T therapies being proposed at the time of first relapse, similar to what has been seen in lymphoma care.
- The paradigm shift in myeloma treatment is towards prioritizing deeper responses, including measurable residual disease (MRD) negativity, as this has been associated with better prognosis and improved long-term outcomes.
Deep dives
The Concept of Minimal Residual Disease in Multiple Myeloma
Minimal residual disease (MRD) or measurable residual disease is a term used to describe the refinement of tools used to measure residual disease in diseases like multiple myeloma. MRD can be measured through technologies like flow cytometry, next generation sequencing, or the measurement of residual monoclonal peptides in the serum of patients. MRD provides a more accurate description of the level of response to treatment, and studies have shown that the attainment of deep responses, including MRD negativity, leads to better long-term outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.